Parse Biosciences Inc., based in Seattle WA, is providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. This latest innovation in single cell genomics allows for unprecedented scale without the limitations of microfluidic droplet-based approaches.
Single cell sequencing has already enabled ground-breaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Parse Biosciences has introduced pioneering technology using combinatorial cDNA barcoding within cells themselves, without a need for cell partitioning instruments. Demonstrating the clear ability to scale, Parse Bio has recently introduced their Evercode Mega Assay for uniquely coding up to a million cells per sample.
